Kay Gene Crop Science Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 16-11-2024
- Paid Up Capital ₹ 2.38 M
as on 16-11-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.94 M
as on 16-11-2024
- Revenue 4.16%
(FY 2023)
- Profit 51.23%
(FY 2023)
- Ebitda -27.28%
(FY 2023)
- Net Worth 7.46%
(FY 2023)
- Total Assets -32.39%
(FY 2023)
About Kay Gene Crop Science
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.38 M.
The company currently has active open charges totaling ₹6.94 M.
Pritam Singh, Vagish Tripathi, and Sanjeev Singh serve as directors at the Company.
- CIN/LLPIN
U01122DL2009PTC190493
- Company No.
190493
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Kay Gene Crop Science Private Limited offer?
Kay Gene Crop Science Private Limited offers a wide range of products and services, including Seeds and Plant Saplings, Vegetable Seeds, Hybrid Seeds, Seeds, Fruit Seeds.
Who are the key members and board of directors at Kay Gene Crop Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vagish Tripathi  | Director | 21-May-2009 | Current |
| Pritam Singh | Director | 25-Jul-2024 | Current |
| Sanjeev Singh | Director | 02-Feb-2016 | Current |
Financial Performance of Kay Gene Crop Science.
Kay Gene Crop Science Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.16% increase. The company also saw a substantial improvement in profitability, with a 51.23% increase in profit. The company's net worth moved up by a moderate rise of 7.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kay Gene Crop Science?
In 2023, Kay Gene Crop Science had a promoter holding of 88.00% and a public holding of 12.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 Feb 2021 | ₹1.77 M | Open |
Hdfc Bank Limited Creation Date: 25 Dec 2018 | ₹5.17 M | Open |
How Many Employees Work at Kay Gene Crop Science?
Unlock and access historical data on people associated with Kay Gene Crop Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kay Gene Crop Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kay Gene Crop Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
